Cooperative Agreement U01CA293859
Award Date 8/4/25
Completion Date 7/31/30
Dollars Obligated $532K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...
- This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,281,520.00 in funding to The Leland Stanford Junior University to conduct research on the fundamental biological mechanisms of cancer metastasis, organ tropism, and immune evasion. The project aims to integrate genetic barcoding with single-cell profiling to uncover the key molecular drivers underlying metastatic fitness and diverse cancer cell states in pancreatic ductal...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This federal Project Grant award of $677,787 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of California, San Francisco (UCSF) to study the role of AIRE-expressing macrophages in tumor immune evasion. The research aims to define novel mechanisms by which tumors evade immune responses, with a focus on the function of these unique macrophage populations in the tumor microenvironment. The project will run from August 2025 through...
- This Project Grant award of $138,846 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a research project to develop "wild-like" laboratory mouse models that better mimic the adult human immune system. The goal is to produce mice with a more mature immune profile, in contrast to the immature immune system typically seen in standard laboratory mice, to enable more accurate translation of cancer and immunotherapy research findings...
- This Project Grant award of $176,712.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh, supports research on immunosurveillance mechanisms that eliminate pre-cancerous cells prior to the formation of malignancies. The primary objective is to investigate how tumor-derived heat shock proteins (HSPs) engage the CD91 receptor on antigen-presenting cells, leading to priming of T cell responses against emerging tumors. This research...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- This federal Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) provides $153,348 to The Trustees of Columbia University in the City of New York to conduct in-depth mechanistic and in vivo functional studies of single-nucleotide variants (SNVs) that modulate T cell activity for cancer immunotherapies. The research aims to define the mechanisms by which certain PIK3CD SNVs enhance T cell activity and evaluate their impact in murine...
- This $112,230 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The University of Texas M.D. Anderson Cancer Center will support research to evaluate the potential of Type 1 conventional dendritic cell (CDC1) vaccination, alone and in combination with anti-CTLA4 immune checkpoint blockade, to induce antigen spread and generate diverse, effective CD8+ T cell responses against melanoma tumors. The project aims to study the ability of CDC1...